JPM | US Healthcare: ARWR/ IONS Deep Dive, CYTK/ EWTX, ROIV, VERA, Biotech Cash Tracker, ELV Day 4, GKOS, COO, DXCM, OLMA and BDX CEO Calls Today
Report Coverage
- Broker
- JPMorgan
- Region
- North America
- Sector
- Information Technology, Healthcare & Biotech
- Report Type
- Economic Report
- Primary Focus
- US biotech and healthcare equity research
Report Summary
JPMorgan provides deep dives on Arrowhead (ARWR) and Ionis (IONS) ahead of the pivotal SHASTA-3/-4 plozasiran data in sHTG, with scenario analysis on acute pancreatitis event reduction. The report also covers the CYTK/EWTX competitive landscape in hypertrophic cardiomyopathy, Vera Therapeutics' atacicept positioning in IgAN versus Otsuka's Voyxact, and the biotech sector's strong cash runway with 61% having 2+ years of funding.
Key Takeaways
- ARWR plozasiran Phase 3 AP event reduction is the key catalyst; Scenario A (CORE-like AP rate) implies ~94% probability of success
- IONS Tryngolza PDUFA on 6/30 with $1bn by 2030 peak sales potential in sHTG; CORE-OLE liver fat data expected this month
- CYTK's aficamten launch in oHCM shows strong early traction; EWTX's EDG-7500 CIRRUS-HCM Part D data near-term catalyst with 55-65% success probability
- VERA's atacicept eGFR data appears directionally superior to Otsuka's Voyxact interim data in IgAN; PDUFA on track for 7/7/26
Why This Report Matters
Multiple pivotal clinical readouts in sHTG, HCM, and IgAN could reshape competitive dynamics across the biotech sector in the coming weeks, with significant stock-moving catalysts.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan JPM report. It helps users review JPM | US Healthcare: ARWR/ IONS Deep Dive, CYTK/ EWTX, ROIV, VERA, Biotech Cash Tracker, ELV Day 4, GKOS, COO, DXCM, OLMA and BDX CEO Calls Today coverage, key takeaways, and related broker or sector research paths across Biotech clinical trial catalysts, HCM competitive landscape analysis, IgAN therapeutic development; Arrowhead Pharmaceuticals, Ionis Pharmaceuticals.
Related Search Paths
Use these links to find similar broker research summaries and sector report notes.